Presented
by

Presented by Oxford Global

Member Login
|
Become a Member

Next Up

Discovery Europe: In-Person

09 - 10 June 2022 |

Berlin, Germany

09 - 10 June 2022

Berlin, Germany

+ Digital Day: 13 June 2022 | Online

Join and network with over 500 industry leaders at the renowned Drug Discovery Summit in Berlin, where we will address the latest advancements in target identification, validation and HIT optimisation.

> Visit Event Website

13 Sep 2022
Tue, 13 September 2022

Emerging Technologies And Methodologies In Small Molecule Drug Discovery & Synthesis Symposium

A three-day event taking place in Toledo, Spain, to explore the latest advancements in organic synthesis, novel therapeutic modalities & approaches in medicinal chemistry, and new organic synthesis methodologies. Organised by Janssen Pharmaceuticals.

More Information Coming Soon

15 Sep 2022
Thu, 15 September 2022

Neuroscience Discovery Symposium

> Visit Event Website

17 Nov 2022
Thu, 17 November 2022

Discovery US: In-Person

500+ leaders, experts and scientists helping to shape the future of drug discovery and development

> Visit Event Website

> See All Upcoming Oxford Global Discovery Events
> See All Webinars & Recordings

Highlights

Colorful chain of amino acids or bio molecules called proteins - 3d illustration
Commentary
PROTACs: “Exciting Opportunities to Explore New Biology”
A Senior Director at AstraZeneca takes us through how the company synthesises and validates novel PROTACs.
By Tom Cohen |
13 May 2022
Targeted Protein Degradation
Insight Article
Getting PROTACs into the Clinic: The Challenges
By Tom Cohen |
21 Apr 2022
Targeted Protein Degradation
Discussion Group Report
AlphaFold and Drug Design: Has AI Solved Biology’s ‘Grand Challenge?’
By Tom Cohen |
21 Apr 2022
Computational Drug Design & AI

In-Depth

Colorful chain of amino acids or bio molecules called proteins - 3d illustration
Commentary
PROTACs: “Exciting Opportunities to Explore New Biology”
A Senior Director at AstraZeneca takes us through how the company synthesises and validates novel PROTACs.
13 May 2022
p53 (blue) tagged with ubiquitin (yellow) is degraded into small peptides by a proteasome (violett). p53 prevents cancer formation and acts as a guardian of the genome. Mutations in the p53 gene contribute to about half of the cases of human cancer.
Insight Article
Getting PROTACs into the Clinic: The Challenges
Oxford Global’s protein degradation panel discussion brought together leading experts in the field to talk about bringing PROTACs to clinical trial endpoints.
21 April 2022
Discussion Group - AI in Drug Design (3 Speakers)
Discussion Group Report
AlphaFold and Drug Design: Has AI Solved Biology’s ‘Grand Challenge?’
Govinda Bhisetti, Principal Investigator and Head of Computational Chemistry at Biogen, leads a discussion group on what the revolutionary machine learning technology means for drug design.
21 April 2022
Medical Laboratory with Team of Scientists Working. Microbiologist is Using Personal Computer, Screen Shows High-Tech Concept for DNA research. High-Tech Biotechnology Research. Back View Shot
Commentary
Merck KGaA: Accelerating Drug Discovery with Automation and Artificial Intelligence
There are innumerable possible compounds in Merck KGaA’s virtual library, so finding drug candidates is only possible with the help of computational methods.
23 March 2022
> See All

[sponsor section - bespoke content]

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Twitter Linkedin-in

Event Series

About

Careers

Legal

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login